Skip to content
  1. Home
  2. >Clinical Genomics
  3. >Hereditary Cancer
  4. >Hereditary Comprehensive Cancer Panel
Back to catalog

Hereditary Comprehensive Cancer Panel

A comprehensive 70-gene panel for assessing hereditary risk across breast, gynecologic, colorectal, pancreatic, prostate, kidney, skin, brain, and endocrine cancers, powered by the Helix Exome+® platform.

Turnaround

6-21 days

Turnaround Requery

≤ 5 days

Panel Description

This panel evaluates 70 genes associated with hereditary cancer conditions that predispose to a variety of primarily adult-onset solid tumors across many organ systems including: breast, gynecologic (ovarian and uterine), colorectal, pancreatic, prostate, kidney, skin, brain and nervous system, and endocrine glands (adrenal, pituitary, parathyroid, thyroid).

View the complete description of this panel
Sample positive result
Sample negative report

Have Questions?

Our team is available Monday through Friday, 9am-5pm Pacific Time.

(844) 211 2070clinicalsupport@helix.com

Indications for Testing

A relevant personal and/or family history suggestive of a hereditary form of cancer.

Methodology

This test utilizes next-generation sequencing to detect single nucleotide variants, insertions and deletions up to 20 bp, and copy number variants in genes associated with a variety of hereditary conditions predisposing to a variety of cancers including: breast, gynecologic (ovarian and uterine), colorectal, pancreatic, prostate, kidney, skin, brain and nervous system, and endocrine glands (adrenal, pituitary, parathyroid, thyroid).

Technical Specifications

Analytical sensitivity (SNV)> 99%Analytical sensitivity (indel)> 99%Analytical specificity> 99%CNV sensitivity (multi-exon)> 99%CNV sensitivity (single-exon)> 90%Gene notesAPC: analysis includes CNV of promoters 1A and 1B and sequencing of promoter 1B; BMPR1A: analysis includes CNV of promoter; BRCA1: sequencing analysis extends to CDS +/-20 bp; BRCA2: analysis includes... Genomic buildGRCh38

Genes Tested

AIP
ALK
APC
ATM
AXIN2
BAP1
BARD1
BLM
BMPR1A
BRCA1
BRCA2
BRIP1
CDC73
CDH1
CDK4
CDKN1B
CDKN2A
CHEK2
CTNNA1
DICER1
EGFR
EPCAM
FH
FLCN
GREM1

Showing 25 of 70 genes in this panel

Other Tests to Consider

Test

Hereditary Breast and Gynecologic Cancers Panel

21

genes

Test

BRCA1 and BRCA2 Panel

2

genes

Test

STAT BRCA1 and BRCA2 Cancer Panel

2

genes

Test

Hereditary Comprehensive Cancer Panel Plus

78

genes

Important Panel Information

Turnaround time: Typically 7-21 days (standard), Typically < 5 days (requery)

Preferred specimen: BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit

Shipping Instructions: Specimens to arrive at Helix within 96 hours of collection at ambient temperature.


This panel includes genes that have an established association with multiple cancer types including breast, colorectal, uterine, ovarian, prostate, kidney, pancreatic, skin, endocrine glands (thyroid, parathyroid, pituitary, adrenal), and nervous system. These genes are primarily associated with adult-onset solid tumors, although some may develop in childhood.

The genes on this panel were specifically selected for their established association with hereditary cancer predisposition. Identification of a pathogenic variant may facilitate increased cancer screening and preventative surgery for early-detection and prevention. Identification of a pathogenic variant also helps identify at-risk family members, who can pursue genetic testing and preventive measures.

The genes on this panel are associated with conditions that have autosomal dominant and/or autosomal recessive inheritance. Note that some of these genes may also be associated with other unrelated conditions; this means that when undergoing this test, there is a possibility of incidentally detecting carrier status for, or predisposition to, one of these unrelated conditions.

Analyzing a wide range of genes in a single test can provide an efficient, cost-effective method of testing for several hereditary cancer conditions. This approach increases the chance of identifying the underlying diagnosis responsible for an individual’s or family’s cancer predisposition.

All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations. Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.